Department of Anesthesiology, Robert Wood Johnson University Hospital, New Brunswick, NJ, USA.
Department of Anesthesiology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Addict Sci Clin Pract. 2024 May 1;19(1):34. doi: 10.1186/s13722-024-00464-8.
Zoledronate, a bisphosphonate, is a potent first-line treatment for osteoporosis. It is also a preferred treatment for hypercalcemia especially when unresponsive to intravenous fluids. Bisphosphonates can cause acute phase reactions that mimic opioid withdrawal symptoms, which can confound provider decision-making. Our case highlights cognitive bias involving a patient with opioid use disorder who received zoledronate for hypercalcemia secondary to immobilization and significant bone infection.
A 41-year-old male is admitted with a past medical history of active intravenous opioid use complicated by group A streptococcal bacteremia with L5-S1 discitis and osteomyelitis, L2-L3 osteomyelitis, and left ankle abscess/septic arthritis status post left ankle washout. His pain was well-controlled by acute pain service with ketamine infusion (discontinued earlier), opioids, acetaminophen, buprenorphine-naloxone, cyclobenzaprine, gabapentin, and naproxen. Intravenous opioids were discontinued, slightly decreasing the opioid regimen. A day later, the patient reported tachycardia, diaphoresis, myalgias, and chills, which the primary team reconsulted acute pain service for opioid withdrawal. However, the patient received a zoledronate infusion for hypercalcemia, on the same day intravenous opioids were discontinued. He had no other medications known to cause withdrawal-like symptoms per chart review. Therefore, it was suspected that an acute phase reaction occurred, commonly seen within a few days of bisphosphonate use.
Zoledronate, well known for causing acute phase reactions, was likely the cause of withdrawal-like symptoms. Acute phase reactions with bisphosphonates mostly occur in the first infusion, and the incidence decreases with subsequent infusions. Symptoms typically occur 24-72 h post-infusion, and last at most for 72 h. Cognitive bias led the primary team to be concerned with opioid withdrawal rather than investigating other causes for the patient's presentation. Therefore, providers should thoroughly investigate potential etiologies and rule them out accordingly to provide the best care. Health care providers should also be aware of the implicit biases that potentially impact the quality of care they provide to patients.
唑来膦酸是一种双膦酸盐,是骨质疏松症的一线强效治疗药物。它也是治疗高钙血症的首选药物,尤其是在对静脉补液无反应时。双膦酸盐会引起急性期反应,类似于阿片类药物戒断症状,这可能会使提供者的决策复杂化。我们的病例重点介绍了认知偏见,涉及一名患有阿片类药物使用障碍的患者,该患者因固定和严重骨感染而接受唑来膦酸治疗高钙血症。
一名 41 岁男性因急性静脉内阿片类药物使用史而入院,该患者并发 A 组链球菌菌血症,L5-S1 椎间盘炎和骨髓炎,L2-L3 骨髓炎和左踝关节脓肿/化脓性关节炎,左踝关节冲洗术后。他的疼痛通过急性疼痛服务得到很好的控制,包括氯胺酮输注(早些时候已停用),阿片类药物,对乙酰氨基酚,丁丙诺啡-纳洛酮,环苯扎林,加巴喷丁和萘普生。静脉内阿片类药物已停用,略减少阿片类药物方案。一天后,患者报告心动过速,出汗,肌痛和寒战,初级团队为此重新咨询急性疼痛服务以治疗阿片类药物戒断。但是,当天停用静脉内阿片类药物后,患者接受了唑来膦酸输注以治疗高钙血症。在回顾图表时,没有发现其他已知会引起戒断样症状的药物。因此,怀疑发生了急性期反应,这种反应通常在使用双膦酸盐后的几天内发生。
唑来膦酸是众所周知的会引起急性期反应的药物,很可能是引起戒断样症状的原因。双膦酸盐的急性期反应主要发生在第一次输注时,随后的输注中发生率降低。症状通常在输注后 24-72 小时出现,最长持续 72 小时。认知偏见使初级团队担心阿片类药物戒断,而不是调查患者病情的其他原因。因此,提供者应彻底调查潜在病因,并相应排除这些病因,以提供最佳的护理。医疗保健提供者还应该意识到潜在的偏见,这些偏见可能会影响他们为患者提供的护理质量。